High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 67, Issue 3, 2007, Pages 257-263

  Blumenfeld, Z ^a   Boulman, N ^a   Leiba, R ^a   Siegler, E ^a   Shachar, S ^b   Linn, R ^b   Levy, Y ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Reproductive Endocrinology   (Israel)

Author keywords

C reactive protein; Cardiovascular disease; Hormone replacement therapy; Levonorgestrel intrauterine system; Transdermal estradiol

Indexed keywords

C REACTIVE PROTEIN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; GESTAGEN; LEVONORGESTREL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; LIVER; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; PROTEIN SYNTHESIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DRUG ADMINISTRATION ROUTES; ESTRADIOL; ESTROGENS, CONJUGATED (USP); FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INFLAMMATION; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; LIPIDS; MEDROXYPROGESTERONE 17-ACETATE; MENOPAUSE; MIDDLE AGED; RISK FACTORS;

EID: 34247347401     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510601113241     Document Type: Article

References (29)

1. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. and the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34.
2. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
3. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS-II). JAMA 2002;288:49-57.
4. Whaley-Connell A, Palmer J, Sowers JR. Can drospirenone with 17-β estradiol safely reduce blood pressure in hypertensive postmenopausal women? [commentary]. Nature Clin Pract Endocrinol Metab 2005;1:72-3.
5. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Inter Med 2002;137:273-84.
6. Mosca L, Collins P, Herrington DM, Mandelsohn ME, Pasternak AC, Robertson RC, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001;104:499-503.
7. Ridker PM, Hennikens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the predictor of cardiovascular disease in women. New Engl J Med 2000;342:836-43.
8. Pearson TA, Mensah GA, Alexander RW. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Center for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
9. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391-7.
10. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713.
11. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Study. Circulation 1999;100:717-22.
12. Post MS, van der Mooren MJ, Stehouwer CD, Van Baal WM, Mijatonic V, Schalkuijk CG, et al. Effect of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: a randomised, placebo-controlled trial. Thromb Haemost 2002;88:605-10.
13. Wanpen V, Meryem T, Zhongyun W, Debbie A, Borna M, Ishwarlal J. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 2003;41:1358-63.
14. Strandberg TE, Ylikorkala O, Tikkanen MJ. Differing effect of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy women. Am J Cardiol 2003;92:212-4.
15. Decensi A, Omodei U, Robertson C, Bonnani B, Guerrierri-Gonzaga A, Ramazzotto F, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in a retinoid-placebo trial in healthy women. Circulation 2002;106:1224-8.
16. Stojanovic ND, Kwong P, Byrne DJ, Arnold A, Jagroop IA, Nair D, et al. The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study. Angiology 2003;54:391-9.
17. Varila E, Wahlstrom T, Rauramo I. A 5-year follow-up study on the use of a levonorgestel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001;76:969-73.
18. Baudner S, Dati F. Protein in human-serum auf der basis des neuen IFCC/BCR/CAP Internationalen Referenzmaterials CRM 470. J Lab Med 1996;20:145-52.
19. Suleiman M, Aronson D, Reisner SA, Kapeliovich MR, Markiewicz W, Levy Y, et al. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am J Med 2003;115:695-701.
20. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004;89:2160-5.
21. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001;103:638-42.
22. Luukkainen T. Issues to debate on the Women's Health Initiative Study. Failure of estrogen plus progestin therapy for prevention of breast cancer risk. Hum Reprod 2003;18:1559-63.
23. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, et al. and the Women's Health Initiative Investigators. Effect of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839-54.
24. Luyer MDP, Khosla S, Owen WG, Miller VM. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrin Metab 2001;86:3629-34.
25. Aronson D, Bartha P, Zinder O, Kerner A, Shitman E, Brook JG, et al. Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet Med 2004;21:39-44.
26. Aronson D, Bartha P, Zinder O, Markiewicz W, Avizohar O, Brook JG, et al. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 2004;28:674-9.
27. Skouby SO, Gram J, Andersen LF, Sidelmann J, Petersen KR, Jespersen J. Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. Am J Obstet Gynecol 2002;186:969-77.
28. Warming L, Ravn P, Christiansen C. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis. Maturitas 2005;14;50:78-85.
29. Hampton NR, Rees MC, Lowe DG, Rauramo I, Barlow D, Guillebaud J. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 2005;20:2653-60.